Is MOTS-c Legal in Pennsylvania?

What MOTS-c Is and Why Its Legal Status Gets Complicated

MOTS-c (Mitochondrial Open Reading Frame of the 12S rRNA-c) is a 16-amino-acid peptide encoded within the mitochondrial genome. Researchers identified it in 2015 when Lee et al. Published in Cell Metabolism showing that MOTS-c acts as a mitochondrial hormone that regulates glucose metabolism and extends lifespan in mice (1). That paper sparked significant clinical interest, and the peptide has since been studied for insulin resistance, obesity, and age-related metabolic decline.

Because MOTS-c is not synthesized in large quantities by any commercial pharmaceutical manufacturer, the supply chain runs almost entirely through research-grade chemical suppliers and, to a smaller extent, compounding pharmacies. That supply chain is precisely where the legal complexity lives.

Why "Natural" Does Not Mean "Legal"

Some direct-to-consumer websites argue that because MOTS-c is "naturally occurring" in the human body, it cannot be regulated as a drug. That argument is legally incorrect. The FDA defines a drug as any article "intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease" or intended to "affect the structure or any function of the body" under 21 U.S.C. § 321(g)(1) (2). Endogenous origin does not exempt a peptide from that definition when it is extracted, synthesized, and sold for therapeutic use.

The Broader Peptide Regulatory Climate

The FDA has been tightening oversight of compounded peptides since 2022. Under that enforcement push, widely used peptides including BPC-157, TB-500, and several others were moved to "Category 2" lists, meaning the agency has concerns about their safety or effectiveness that preclude bulk compounding. MOTS-c has not yet received a final formal ruling, but its absence from the approved 503A Bulks List places it in the same functionally restricted space. Practitioners prescribing it do so in a documented gray area.

Federal Law: The FDA Framework That Governs MOTS-c Everywhere in the U.S.

Federal law establishes the floor for MOTS-c regulation in all 50 states. Pennsylvania cannot unilaterally legalize something the FDA has restricted, and it cannot independently permit a pharmacy to compound a substance that fails federal bulk-substance criteria.

The 503A and 503B Compounding Pathways

The Drug Quality and Security Act of 2013 created two compounding categories (3):

503A pharmacies are traditional compounding pharmacies. They may prepare a drug from bulk substances only if the substance appears on the FDA's approved Bulks List (or is a USP/NF-listed substance). MOTS-c does not appear on the current 503A Bulks List. A 503A pharmacy that compounds MOTS-c is therefore preparing an adulterated or misbranded drug under federal law unless the agency has issued interim enforcement discretion.

503B outsourcing facilities operate under stricter cGMP standards and may compound from bulk substances that appear on a separate 503B list. MOTS-c does not appear on that list either.

The practical result: no compounding pharmacy in Pennsylvania or anywhere else in the U.S. Can legally prepare MOTS-c under the standard compounding framework as of mid-2025.

Enforcement Discretion and the "Gray Area"

The FDA does not have unlimited enforcement resources. For peptides that sit outside both Bulks Lists, the agency sometimes exercises enforcement discretion, choosing not to pursue action against a specific pharmacy or prescriber while a substance is under formal review. MOTS-c is neither expressly prohibited nor expressly permitted in that interim space. The FDA's guidance document on bulk drug substances states that compounding from a bulk substance not on the Bulks List is "generally not appropriate" but acknowledges that the agency prioritizes enforcement based on risk (4). That language is where most telehealth platforms cite when they offer MOTS-c today. The honest clinical description is: the practice is legally uncertain and subject to change.

Research Use

MOTS-c purchased as a research chemical is technically legal for laboratory use in cell studies or animal models. It is not legal for human administration under a "research use only" label. The FDA's position on this is clear: relabeling a research chemical for therapeutic use in humans is an unapproved new drug application violation (2).

Pennsylvania State Law: What Applies on Top of Federal Rules

Pennsylvania does not have a MOTS-c-specific statute. The state has not placed MOTS-c on any controlled substance schedule, and the Pennsylvania Department of Health has not issued a bulletin specifically restricting or permitting it. What Pennsylvania does have is a regulatory architecture that governs prescribing and compounding in ways that interact directly with MOTS-c's federal status.

Pennsylvania State Board of Pharmacy

The Pennsylvania State Board of Pharmacy licenses pharmacies operating within the commonwealth under the Pharmacy Act (63 P.S. § 390-1 et seq.) (5). Licensed pharmacies must comply with both state compounding regulations and federal law. A Pennsylvania pharmacy cannot shelter behind state silence on MOTS-c to avoid the federal Bulks List requirement. The Board has the authority to discipline a pharmacy for compounding a substance that violates federal standards, and it has exercised that authority in analogous situations involving other unapproved bulk substances.

Pennsylvania Medical Practice Act and Prescriber Liability

Under the Pennsylvania Medical Practice Act of 1985 (63 P.S. § 422.1 et seq.), a physician may prescribe any legal drug within the bounds of accepted medical practice. "Accepted medical practice" is interpreted by the Pennsylvania State Board of Medicine and shaped by peer-reviewed evidence. Because MOTS-c lacks Phase III trial data and FDA approval, prescribing it sits outside standard of care. That does not make prescribing automatically illegal, but it does create a documentation burden: the physician must be able to demonstrate that the prescription was issued within a valid physician-patient relationship, that the patient was informed of the experimental nature of the treatment, and that a legitimate medical purpose exists (6).

Telehealth Prescribing in Pennsylvania

Pennsylvania permits telehealth prescribing under Act 25 of 2020, which codified temporary COVID-era telehealth rules into permanent statute. A physician licensed in Pennsylvania may establish a valid patient-physician relationship via synchronous audiovisual encounter and then prescribe within the bounds of their license. For MOTS-c, that means a Pennsylvania-licensed telehealth physician can write a prescription, but the pharmacy receiving that prescription still faces the federal Bulks List problem described above. Telehealth removes a geographic barrier but does not resolve the compounding-law barrier.

What the Clinical Evidence Actually Shows

Legal status questions should be grounded in the underlying science. Understanding where MOTS-c stands clinically helps explain why the FDA has not moved faster to either approve or explicitly ban it.

Preclinical and Early Human Data

The 2015 Lee et al. Cell Metabolism study (referenced above) showed that MOTS-c administration in mice improved insulin sensitivity and reduced fat accumulation on a high-fat diet (1). A 2019 follow-up by Lee et al. In Nature Communications (N = small cohort of older adults, observational) found that circulating MOTS-c levels declined with age and correlated inversely with metabolic syndrome markers (7). Neither paper constitutes the controlled Phase III human trial data the FDA requires for approval.

A 2021 study published in Aging examined MOTS-c's role in exercise adaptation. The authors found that exogenous MOTS-c administration in aged mice increased skeletal muscle glucose uptake at a level comparable to young controls, acting through the AMPK pathway (8). AMPK activation is mechanistically plausible in humans, but the translational step has not been validated in a registered Phase II or III clinical trial as of this writing.

The Human Trial Gap

No completed Phase III randomized controlled trial on MOTS-c exists in ClinicalTrials.gov as of July 2025. There are registered early-phase studies, including a Phase I dose-escalation study examining safety and pharmacokinetics in healthy volunteers. Until those data are published and reviewed, the FDA has no evidentiary basis to approve MOTS-c, and practitioners are operating on mechanistic rationale and preclinical extrapolation.

A Clinical Decision Framework for Pennsylvania Prescribers

For Pennsylvania-licensed physicians considering MOTS-c prescriptions, a defensible documentation framework includes four elements:

1. A comprehensive metabolic workup establishing a clinical indication (e.g., documented insulin resistance via HOMA-IR, confirmed mitochondrial dysfunction, or refractory obesity with BMI <40 where GLP-1 therapy has been attempted and failed).
2. Informed consent documentation specifically noting that MOTS-c is not FDA-approved, lacks Phase III trial data, and is being prescribed off-label within a federal gray area.
3. A pharmacy relationship with a 503A compounder that has requested and received written FDA enforcement-discretion guidance, or that operates under a Named Patient/investigational pathway.
4. Ongoing metabolic monitoring at 8-week intervals with dose adjustment tied to objective lab markers (fasting insulin, HbA1c, lipid panel).

How to Get MOTS-c in Pennsylvania: Realistic Pathways

Given the legal field above, Pennsylvania residents have three realistic pathways, each with a different risk-benefit and legal-certainty profile.

Pathway 1: Telehealth Prescription Through a Compounding-Affiliated Platform

Several national telehealth platforms work with 503A compounding pharmacies that are currently supplying MOTS-c under enforcement discretion. A Pennsylvania resident can complete a telehealth visit with a Pennsylvania-licensed physician, receive a prescription, and have the compound shipped to a Pennsylvania address. This is the most common pathway in 2025. The legal risk is real but currently low in practical terms because FDA enforcement against individual patients has not been a documented priority.

Pathway 2: Investigational Access or Clinical Trial Enrollment

Patients with documented metabolic conditions may qualify for early-phase trials administering MOTS-c. ClinicalTrials.gov is the appropriate starting point. This pathway provides the highest legal certainty (FDA oversight covers the trial) and the benefit of structured monitoring, but availability is geographically and clinically restricted.

Pathway 3: Research Chemical Purchase (Not Recommended for Self-Administration)

MOTS-c is sold by multiple suppliers as a research chemical. Purchasing it for laboratory use is legal. Self-administering it based on a research-grade supply chain is not. Beyond the legal issue, research-grade peptides are not manufactured under pharmaceutical-grade GMP standards, meaning purity and sterility cannot be guaranteed. The FDA's guidance on compounding states that lack of sterility testing in non-GMP environments creates direct patient-safety risk (4). This pathway is included here for completeness and accuracy, not as a recommendation.

Risks of Obtaining MOTS-c Outside a Licensed Clinical Setting

Operating outside a licensed prescriber-pharmacy relationship carries documented risks beyond legal exposure.

Purity and Sterility Concerns

A 2020 analysis published in JAMA Internal Medicine reviewed peptide products purchased from commercial suppliers and found that 44% of samples contained substances not listed on the label, including bacterial endotoxins (9). Subcutaneous injection of a contaminated peptide can produce injection-site infections, systemic inflammatory responses, or, in the worst cases, sepsis.

Dosing Unknowns

Human pharmacokinetic data for MOTS-c are limited. The 2015 Lee et al. Paper used intraperitoneal doses of 15 mg/kg in mice. Human dose translation using standard allometric scaling does not produce a validated clinical dose. A physician prescribing MOTS-c through a compounding pharmacy typically uses 5 mg to 10 mg subcutaneous doses 2 to 3 times weekly based on practitioner experience, not a controlled dose-finding trial. Self-dosing without medical guidance amplifies that uncertainty.

Regulatory Exposure for the Patient

Individual patients who self-administer research chemicals are not typically prosecuted under federal drug law. However, patients who purchase MOTS-c through a compounding pharmacy that later receives an FDA warning letter may find their supply cut off abruptly, creating a discontinuation problem for ongoing therapy.

Physician and Pharmacy Obligations in Pennsylvania

A Pennsylvania physician who prescribes MOTS-c must document a valid physician-patient relationship per the Pennsylvania Medical Practice Act. The prescription must be written for a specific patient, specify the compound, concentration, route, and dosing schedule, and be transmitted to a licensed pharmacy. Writing a blanket prescription for a clinic's general inventory (a practice sometimes called "office use" compounding) violates both federal compounding law and Pennsylvania Board of Medicine regulations.

A Pennsylvania-licensed 503A pharmacy that receives a MOTS-c prescription must assess whether it can legally compound that substance. The Pennsylvania State Board of Pharmacy's compounding regulations, updated in 2019 under 49 Pa. Code § 27.201, require compliance with USP Chapter 797 for sterile compounding and federal bulk-substance requirements (5). Most Pennsylvania pharmacies currently decline MOTS-c compounding precisely because of the Bulks List gap. Patients receiving MOTS-c through a Pennsylvania address typically receive it from an out-of-state 503A pharmacy licensed to ship interstate.

The FDA's compliance guidance notes: "A compounder that uses a bulk drug substance not on the list of bulk drug substances that may be used in compounding... May be subject to enforcement action." (4) That statement applies to pharmacies shipping into Pennsylvania just as it does to those physically located in the commonwealth.

Monitoring and Safety Protocols for Patients Currently Using MOTS-c

Patients who are already using MOTS-c under a physician's supervision in Pennsylvania should follow a structured monitoring protocol to document both clinical effect and safety.

Baseline Labs Before Starting

A reasonable pre-therapy metabolic panel includes: fasting glucose, fasting insulin (for HOMA-IR calculation), HbA1c, a comprehensive metabolic panel, CBC, lipid panel, and a thyroid panel. Because MOTS-c acts through AMPK and affects mitochondrial metabolism, liver function markers are particularly relevant.

Monitoring at 8 Weeks

Repeat fasting glucose, fasting insulin, and liver enzymes at 8 weeks. An objective response (reduction in HOMA-IR by >15% from baseline) provides the physician with documented clinical justification for continuing. Absence of response at 12 weeks is a reasonable stopping criterion given the limited evidence base.

Injection Site Management

MOTS-c is administered subcutaneously, typically in the abdomen or lateral thigh. Patients should rotate injection sites and inspect for erythema, induration, or signs of infection at each administration. Any injection-site reaction lasting more than 72 hours warrants clinical evaluation.